Prot# VX11-222-106: A Multicenter, Randomized, Double-blind, Placebo- Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subje

Project: Research project

Project Details

StatusFinished
Effective start/end date3/15/123/15/16

Funding

  • Parexel (VX11-222-106 // VX11-222-106)
  • Vertex Pharmaceuticals Incorporated (VX11-222-106 // VX11-222-106)